Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
- DSP Launches Myslee Generic on June 28
June 28, 2012
- Eisai to Make Full-Scale Entry into Russian Market; Antiepileptic Agent Obtains Approval
June 28, 2012
- Yoshindo to Accumulate Know-How to Develop Biopharmaceutical Products through Contract Manufacturing
June 28, 2012
- Astellas Files MAA for Anti-Androgen Agent MDV3100 in Europe
June 28, 2012
- Chugai Applies for Tarceva for NSCLC First-Line Therapy
June 28, 2012
- Takata Seiyaku to Market 3 Products from Shionogi
June 28, 2012
- MSs Want “Client Visits by MRs” for Generic Promotion: Toho Pharmaceutical Survey
June 27, 2012
- Large Number of GEs Could Become Serious Issue: Alfresa Logistics Chief Fukujin
June 27, 2012
- Takeda to Market Iron Deficiency Anemia Drug in Europe
June 27, 2012
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
- Otsuka, UCB Japan Apply for E Keppra for Pediatric Epilepsy
June 25, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…